- Home
- FORA vs VSTM Comparison
FORA vs VSTM Comparison
Compare FORA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- VSTM
- Stock Information
- Founded
- FORA 2014
- VSTM 2010
- Country
- FORA United States
- VSTM United States
- Employees
- FORA N/A
- VSTM N/A
- Industry
- FORA Computer Software: Prepackaged Software
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- VSTM Health Care
- Exchange
- FORA Nasdaq
- VSTM Nasdaq
- Market Cap
- FORA 63.8M
- VSTM 132.0M
- IPO Year
- FORA N/A
- VSTM 2012
- Fundamental
- Price
- FORA $2.10
- VSTM $3.88
- Analyst Decision
- FORA Strong Buy
- VSTM Strong Buy
- Analyst Count
- FORA 1
- VSTM 8
- Target Price
- FORA $5.00
- VSTM $14.57
- AVG Volume (30 Days)
- FORA 14.2K
- VSTM 1.1M
- Earning Date
- FORA 11-07-2024
- VSTM 11-06-2024
- Dividend Yield
- FORA N/A
- VSTM N/A
- EPS Growth
- FORA N/A
- VSTM N/A
- EPS
- FORA 0.06
- VSTM N/A
- Revenue
- FORA $20,371,880.00
- VSTM $10,000,000.00
- Revenue This Year
- FORA N/A
- VSTM N/A
- Revenue Next Year
- FORA $10.64
- VSTM $125.69
- P/E Ratio
- FORA $36.34
- VSTM N/A
- Revenue Growth
- FORA 6.97
- VSTM N/A
- 52 Week Low
- FORA $2.00
- VSTM $2.10
- 52 Week High
- FORA $4.15
- VSTM $14.22
- Technical
- Relative Strength Index (RSI)
- FORA 38.13
- VSTM 63.77
- Support Level
- FORA $2.05
- VSTM $3.11
- Resistance Level
- FORA $2.16
- VSTM $3.76
- Average True Range (ATR)
- FORA 0.05
- VSTM 0.33
- MACD
- FORA 0.00
- VSTM 0.04
- Stochastic Oscillator
- FORA 31.77
- VSTM 94.26
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.